Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 14/20 | 0.42 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14034821 | 0.87 | EGLN1 (0.41) | EGLN1HIF1AERCC1FEN1ERCC4 | |
| SCHEMBL2497612 | 0.82 | EGLN1 (0.53) | EGLN1HIF1A | |
| SCHEMBL2495407 | 0.81 | EGLN1 (0.53) | EGLN1HIF1A | |
| SCHEMBL2578325 | 0.81 | EGLN1 (0.53) | EGLN1HIF1A | |
| SCHEMBL2498913 | 0.81 | EGLN1 (0.50) | EGLN1HIF1AKDM4EALDH1A1 | |
| SCHEMBL2493062 | 0.79 | EGLN1 (0.56) | EGLN1HIF1A | |
| SCHEMBL337509 | 0.78 | EGLN1 (0.51) | EGLN1HIF1A | |
| SCHEMBL2495911 | 0.76 | EGLN1 (0.53) | EGLN1HIF1A | |
| SCHEMBL2498193 | 0.74 | EGLN1 (0.51) | EGLN1HIF1A | |
| SCHEMBL2385741 | 0.73 | HIF1A (0.62) | EGLN1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150251-B9 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2013-02-27 | — | — | EP | claimed |
| EP-2150251-B1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2012-06-27 | — | — | EP | claimed |
| US-8030346-B2 | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2011-10-04 | — | — | US | claimed |
| EP-2150251-A1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | Amgen, Inc (US) | 2010-02-10 | — | — | EP | claimed |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-06-18 | — | — | US | claimed |
| WO-2008137060-A1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC. (US) | 2008-11-13 | — | — | WO | claimed |
| EP-2150251-B9 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2150251-B9 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2150251-B1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2150251-B1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8030346-B2 | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030346-B2 | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030346-B2 | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2150251-A1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | Amgen, Inc (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008137060-A1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | EGLN3, HIF1AN, EGLN2 | EGLN1 6/4885HIF1A 4/4885ERCC1 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.